Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Business & Regulation

Business & Regulation Profession

Full Disclosure

| Maryam Mahdi

Oncologists frequently receive “gifts” from pharma companies, but how much is too much?

Business & Regulation Advanced Medicine

Let's Meet in the Middle

| Bill Milligan

As long as payers recognize the value of a curative treatment and manufacturers are flexible with payment plans, patients will have access to ATMPs.

Business & Regulation Advanced Medicine

Cell and Gene Pricing: How Can Manufacturers Get it Right?

| Ana Stojanovska

For manufacturers, educating stakeholders, generating evidence and putting the patient first are key to getting value based contracts right.

Business & Regulation Standards & Regulation

So Long and Thanks for all the Drugs

| Stephanie Sutton

Scott Gottlieb prepares to leave the FDA after accomplishing much.

Business & Regulation Standards & Regulation

Tax Credits: Your Work is Worth it

| Peter Beavis

Research and development tax reliefs are available for businesses in many countries, but some companies are not taking advantage.

Business & Regulation Standards & Regulation

A Fairer Playing Field

| Maryam Mahdi

A recently published report shows how the European Commission has protected patients against anticompetitive practices over the last decade.

Business & Regulation Advanced Medicine

Advanced Therapies: The Price is Right?

| Dan Ollendorf

Are healthcare systems and manufacturers ready to embrace evidence-based pricing to lessen the impact of upfront costs of advanced therapies?

Business & Regulation Advanced Medicine

Building a Business: Lessons Learned with Angela Osborne

| Maryam Mahdi

Angela Osborne has created her own space in the industry and is helping the cell and gene therapy industry bloom.

Business & Regulation Quality & Compliance

Batch Relief

| James Strachan

EU will allow companies to carry out QC testing in the UK after a "no deal" Brexit, at least under certain conditions and for a limited time.

Business & Regulation Advanced Medicine

C&G Therapy? That’ll Do NICEly

| James Strachan

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

Newsletter

Send me the latest from The Medicine Maker.

Sign up now

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register